Neuclone Reports Dosing of NeuLara (biosimilar, ustekinumab) in P-I Trial

 Neuclone Reports Dosing of NeuLara (biosimilar, ustekinumab) in P-I Trial

NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia


  • The P-I trial involves assessing of Stelara (US or EU) vs NeuLara in 210 patients in ratio (1:1:1) and resulted in no serious adverse events with anticipated results in Q3’20
  • NeuLara is one of the biosimilars developed in collaboration with NeuClone and Serum Institute of India Pvt Ltd (Serum Institute). In 2009, Stelara was launched in the US and its Wholesale Acquisition Cost (WAC) increased by 136%
  • NeuClone has a pipeline of biosimilars referencing Herceptin, Stelara, Synagis, Prolia/XGEVA, Perjeta and Humira developed using its NeuMAX platform

Click here to read full press release/ article | Ref: Neuclone | Image: Signbox

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on

Related post